{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:25:52Z","timestamp":1778617552383,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210204092YY"],"award-info":[{"award-number":["20210204092YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210204092YY"],"award-info":[{"award-number":["20210204092YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210204092YY"],"award-info":[{"award-number":["20210204092YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Department of Science and Technology of Jilin Province","doi-asserted-by":"publisher","award":["20210204092YY"],"award-info":[{"award-number":["20210204092YY"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-98813-3","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:29:20Z","timestamp":1746606560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigation into the pharmacodynamics and pharmacokinetics of recombinant human interferon alfa-2b vaginal suppository following process optimization in chinese rhesus macaque"],"prefix":"10.1038","volume":"15","author":[{"given":"Xueyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baisong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"927","key":"98813_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R Soc. Lond. B Biol. Sci. 147 (927), 258\u2013267 (1957).","journal-title":"Proc. R Soc. Lond. B Biol. Sci."},{"issue":"5","key":"98813_CR2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.survophthal.2022.03.003","volume":"67","author":"P Cid\u2043Bertomeu","year":"2022","unstructured":"Cid\u2043Bertomeu, P. & Huerva, V. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma. Surv. Ophthalmol. 67 (5), 1391\u20131404 (2022).","journal-title":"Surv. Ophthalmol."},{"key":"98813_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2021.04.049","volume":"107","author":"YZ Ye","year":"2021","unstructured":"Ye, Y. Z. et al. Efficacy and safety of interferon \u03b1\u20432b spray for herpangina in children: a randomized, controlled trial. Int. J. Infect. Dis. 107, 62\u201368 (2021).","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"98813_CR4","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger, H. et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 7 (3), e196\u2013e208 (2020).","journal-title":"Lancet Haematol."},{"key":"98813_CR5","first-page":"100360","volume":"19","author":"J Okikiolu","year":"2022","unstructured":"Okikiolu, J. et al. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk. Res. Rep. 19, 100360 (2022).","journal-title":"Leuk. Res. Rep."},{"key":"98813_CR6","doi-asserted-by":"publisher","first-page":"204062072412295","DOI":"10.1177\/20406207241229588","volume":"15","author":"P Vachhani","year":"2024","unstructured":"Vachhani, P. et al. Interferons in the treatment of myeloproliferative neoplasms. Ther. Adv. Hematol. 15, 20406207241229588 (2024).","journal-title":"Ther. Adv. Hematol."},{"issue":"6","key":"98813_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","volume":"14","author":"YW Huang","year":"2020","unstructured":"Huang, Y. W. et al. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Hepatol. Int. 14 (6), 997\u20131008 (2020).","journal-title":"Hepatol. Int."},{"issue":"3","key":"98813_CR8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","volume":"120","author":"SJ Hsu","year":"2021","unstructured":"Hsu, S. J. et al. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. J. Formos. Med. Assoc. 120 (3), 956\u2013964 (2021).","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"98813_CR9","first-page":"85","volume":"26","author":"MR Fazeli","year":"2022","unstructured":"Fazeli, M. R. & Hezarjaribi, N. A simplified process for purification and refolding of Recombinant human Interferon-\u03b12b. Iran. Biomed. J. 26 (1), 85\u201390 (2022).","journal-title":"Iran. Biomed. J."},{"key":"98813_CR10","doi-asserted-by":"crossref","unstructured":"Sun, Y., Xu, J., Zhou, H., You, L. & Zhu, Y. Influence of Lacidophilin Vaginal Capsules plus rh-IFN-\u03b12b on Efficacy, Vaginal Microecology, and Safety of Patients with HPV Infection. Evid Based Complement Alternat Med. ; 2022:3632053. (2022).","DOI":"10.1155\/2022\/3632053"},{"issue":"6","key":"98813_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/v16060989","volume":"16","author":"A Ivanina","year":"2024","unstructured":"Ivanina, A. et al. The topical novel formulations of interferon \u03b1-2\u0432 effectively inhibit HSV-1 keratitis in the rabbit eye model and HSV-2 genital herpes in mice. Viruses 16 (6), 989 (2024).","journal-title":"Viruses"},{"issue":"11","key":"98813_CR12","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1021\/acs.molpharmaceut.9b00719","volume":"16","author":"S Bandi","year":"2019","unstructured":"Bandi, S., Singh, S. M., Shah, D. D., Upadhyay, V. & Mallela, K. M. G. 2D NMR analysis of the effect of asparagine deamidation versus methionine oxidation on the structure, stability, aggregation, and function of a therapeutic protein. Mol. Pharm. 16 (11), 4621\u20134635 (2019).","journal-title":"Mol. Pharm."},{"key":"98813_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.procbio.2021.08.029","volume":"111","author":"A Shaldzhyan","year":"2021","unstructured":"Shaldzhyan, A. et al. Clean and folded: production of active, high quality Recombinant human interferon-\u03bb1. Process. Biochem. 111, 32\u201339 (2021).","journal-title":"Process. Biochem."},{"key":"98813_CR14","doi-asserted-by":"publisher","first-page":"106125","DOI":"10.1016\/j.pep.2022.106125","volume":"198","author":"C Wilkinson","year":"2022","unstructured":"Wilkinson, C. et al. Improved yield of Recombinant human IFN-\u03b12b from mammalian cells using heterologous signal peptide approach. Protein Expr Purif. 198, 106125 (2022).","journal-title":"Protein Expr Purif."},{"key":"98813_CR15","doi-asserted-by":"publisher","first-page":"108888","DOI":"10.1016\/j.clim.2021.108888","volume":"233","author":"SI Giorgetti","year":"2021","unstructured":"Giorgetti, S. I. et al. Development of highly stable and de-immunized versions of Recombinant alpha interferon: promising candidates for the treatment of chronic and emerging viral diseases. Clin. Immunol. 233, 108888 (2021).","journal-title":"Clin. Immunol."},{"issue":"5","key":"98813_CR16","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ijms25052751","volume":"25","author":"SF Carvalho","year":"2024","unstructured":"Carvalho, S. F., Pereiro, A. B. & Ara\u00fajo, J. M. M. Simultaneous purification of human interferon Alpha-2b and serum albumin using bioprivileged fluorinated ionic Liquid-Based aqueous biphasic systems. Int. J. Mol. Sci. 25 (5), 2751 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"98813_CR17","doi-asserted-by":"publisher","first-page":"2292688","DOI":"10.1080\/19420862.2023.2292688","volume":"16","author":"M Li","year":"2024","unstructured":"Li, M. et al. Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches. MAbs 16 (1), 2292688 (2024).","journal-title":"MAbs"},{"issue":"7","key":"98813_CR18","first-page":"1203","volume":"41","author":"HR Yin","year":"2021","unstructured":"Yin, H. R. et al. Study of methionine oxidization in human interferon \u03b1 2b using HPLC and UPLC\u2043Q\u2043TOF\u2043MS. Chin. J. Pharm. Anal. 41 (7), 1203\u20131208 (2021).","journal-title":"Chin. J. Pharm. Anal."},{"key":"98813_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.freeradbiomed.2020.02.014","volume":"150","author":"T Grune","year":"2020","unstructured":"Grune, T. Oxidized protein aggregates: formation and biological effects. Free Radic Biol. Med. 150, 120\u2013124 (2020).","journal-title":"Free Radic Biol. Med."},{"issue":"3","key":"98813_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.xphs.2020.12.003","volume":"110","author":"Y Wen","year":"2021","unstructured":"Wen, Y. & Jawa, V. The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics. J. Pharm. Sci. 110 (3), 1025\u20131041 (2021).","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"98813_CR21","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1016\/j.xphs.2020.07.029","volume":"109","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Simultaneous monitoring and comparison of multiple product quality attributes for cell culture processes at different scales using a LC\/MS\/MS based Multi-Attribute method. J. Pharm. Sci. 109 (11), 3319\u20133329 (2020).","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"98813_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1055\/a-2185-4916","volume":"74","author":"RS Nunavath","year":"2024","unstructured":"Nunavath, R. S. et al. Quality by design in pharmaceuticals: A review of its impact on regulatory compliance and product quality. Drug Res. (Stuttg). 74 (1), 18\u201323 (2024).","journal-title":"Drug Res. (Stuttg)"},{"key":"98813_CR23","unstructured":"Committe National Pharmacopoeia. Pharmacopoeia of People\u2019s Republic of China[M]. Part 1 (Beijing; China Medical Science Press., 2020)."},{"key":"98813_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi, N., Zagrijtschuk, O., Kang, L., Yonezu, K. & Qin, A. Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin. Drug Investig. 41, 391\u2013404 (2021).","journal-title":"Clin. Drug Investig"},{"issue":"3","key":"98813_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1358\/dot.2020.56.3.3107706","volume":"56","author":"SM Wagner","year":"2020","unstructured":"Wagner, S. M., Melchardt, T. & Greil, R. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera. Drugs Today (Barc). 56 (3), 195\u2013202 (2020).","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"98813_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/v14061128","volume":"14","author":"YW Huang","year":"2022","unstructured":"Huang, Y. W., Qin, A., Tsai, C. Y. & Chen, P. J. Novel pegylated interferon for the treatment of chronic viral hepatitis. Viruses 14 (6), 1128 (2022).","journal-title":"Viruses"},{"key":"98813_CR27","first-page":"3599","volume":"44","author":"BE Sumpio","year":"1984","unstructured":"Sumpio, B. E., Ernstoff, M. S. & Kirkwood, J. M. Urinary excretion of interferon, albumin, and beta 2-mi-croglobulin during interferon treatment. Cancer Res. 44, 3599\u20133603 (1984).","journal-title":"Cancer Res."},{"issue":"4","key":"98813_CR28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi, N., Zagrijtschuk, O., Kang, L., Yonezu, K. & Qin, A. Pharmacokinetics and pharmacodynamics of ropeginterferon Alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin. Drug Investig. 41 (4), 391\u2013404 (2021).","journal-title":"Clin. Drug Investig"},{"key":"98813_CR29","doi-asserted-by":"crossref","unstructured":"Li, R. et al. Guttate psoriasis induced by interferon alfa-2b suppository treatment for high-grade cervical intraepithelial neoplasia. Dermatol. Ther. ;): e11 ): e15834. (2022).","DOI":"10.1111\/dth.15834"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98813-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:29:28Z","timestamp":1746606568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98813-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98813"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98813-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5354253\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The funding sources had no role in the design and conduct of the study; collection,management, analysis, and interpretation of the data; preparation, review, or approval of the.manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the funder"}},{"value":"No potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"15932"}}